Design, synthesis and evaluation of 3,4-dihydroxybenzoic acid derivatives as antioxidants, bio-metal chelating agents and acetylcholinesterase inhibitors

References

• Myhre O, Utkilen H, Duale N, et al. Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. Oxid Med Cell Longev 2013; 2013:art. no. 726954
   PubMed Web of Science ®Google Scholar
• Kozlowski H, Luczkowski M, Remelli M, Valensin D. Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases). Coordin Chem Rev 2012;256:2129–41
   Web of Science ®Google Scholar
• Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010;345:91–104
   PubMed Web of Science ®Google Scholar
• Molina-Holgado F, Hider RC, Gaeta A, et al. Metals ions and neurodegeneration. Biometals 2007;20:639–54
   PubMed Web of Science ®Google Scholar
• Ward RJ, Dexter DT, Crichton RR. Chelating agents for neurodegenerative diseases. Curr Med Chem 2012;19:2760–72
   PubMed Web of Science ®Google Scholar
• Mao F, Huang L, Luo Z, et al. O-Hydroxyl- or o-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-β aggregation. Bioorg Med Chem 2012;20:5884–92
   PubMed Web of Science ®Google Scholar
• Fernandez-Bachiller MI, Perez C, Campillo NE, et al. Tacrine–melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 2009;4:828–41
   PubMed Web of Science ®Google Scholar
• Fernández-Bachiller MI, Pérez C, Monjas L, et al. New tacrine-4-Oxo-4 H-chromene hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J Med Chem 2012;55:1303–17
   PubMed Web of Science ®Google Scholar
• Leon R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev 2013;33:139--89
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol 2011;4:293–8
   PubMedGoogle Scholar
• Youdim MBH, Buccafusco JJ. CNS targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases. J Neural Transm 2005;112:519–37
   PubMed Web of Science ®Google Scholar
• Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006;545:51–64
   PubMed Web of Science ®Google Scholar
• Ordoudi SA, Tsimidou MZ, Vafiadis AP, Bakalbassis EG. Structure-DPPH• scavenging activity relationships: parallel study of catechol and guaiacol acid derivatives. J Agric Food Chem 2006;54:5763–8
   PubMed Web of Science ®Google Scholar
• Mandel S, Amit T, Bar-Am O, Youdim MBH. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 2007;82:348–60
   PubMed Web of Science ®Google Scholar
• Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011;221:555–63
   PubMed Web of Science ®Google Scholar
• Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res 2013;36:375–99
   PubMed Web of Science ®Google Scholar
• Brand-Williams W, Cuvelier ME, Berset C. Use of a free radical method to evaluate antioxidant activity. LWT Food Sci Technol 1995;28:25–30
   Web of Science ®Google Scholar
• Vosburgh WC, Cooper GR. Complex ions. I. The identification of complex ions in solution by spectrophotometric measurements. J Am Chem Soc 1941;63:437–42
   Google Scholar
• Foley RT, Anderson RC. Spectrophotometric studies on complex formation with sulfosalicylic acid. I. With iron III. J Am Chem Soc 1948;70:1195–7
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–90
   PubMed Web of Science ®Google Scholar
• Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011;39:W270–7
   PubMed Web of Science ®Google Scholar
• Zoete V, Cuendet MA, Grosdidier A, Michielin O. SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 2011;32:2359–68
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605–12
   PubMed Web of Science ®Google Scholar
• Cappelli A, Gallelli A, Manini M, et al. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. Development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties. J Med Chem 2005;48:3564–75
   PubMed Web of Science ®Google Scholar
• Alcaro S, Arcone R, Costa G, et al. Simple choline esters as potential anti-alzheimer agents. Curr Pharm Des 2010;16:692–7
   PubMed Web of Science ®Google Scholar